ASH Preview - Novel drug classes facing important tests

Date December 07, 2011

The meeting of the American Society of Hematology (ASH) is last on the annual schedule of major medical meetings but certainly not least in terms of the importance of scientific data presented. This year, phase II trial results from YM Biosciences’ CYT387 in myelofibrosis and Ariad Pharmaceuticals’ ponatinib in chronic myeloid leukaemia (CML) have the potential to spark significant share price gains and advance partnering talks should the data be positive.

Also on the agenda for the meeting, beginning Saturday, is mid-stage data from Pharmacyclics’ PCI-32765 in chronic and small lymphocytic leukaemia (CLL/SLL). Investors will be hoping to see positive confirmatory data to support its impressive share price growth through 2011 (Trial success opening doors for Pharmacyclics, June 15, 2011).

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd